Sionna Therapeutics, Inc. Common Stock

Day range

$3.57 – $3.69

Open

$3.58

Prev close

$3.60

Volume

294.79K

Market cap

$162.76M

Shares out

45.21M

P/E

—

P/S

—

P/B

0.61

P/FCF

—

ROE

-36.6%

ROA

-34.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive officer appointmentSep 14, 2026

  The Board approved the following changes to the roles and responsibilities of certain of the Company's executive officers ... Charlotte McKee ... assumed the additional role of Head of Research and Development; (ii) Elena Ridloff ... assumed the additional role of Chief Business Officer; and (iii) Jennifer Fitzpatrick ... assumed the additional role of Head of Program Management.

• Strategic initiativeAug 10, 2026

  The Company also provided a corporate update, including that it is not advancing SION-719 as an add-on to standard of care and plans to preserve capital while evaluating next steps for its SION-451 dual combination program.

• Annual meeting resultsJun 18, 2026

  On June 17, 2026, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. Based on the foregoing votes, each of the nominees was elected as a Class II director and the appointment of Deloitte & Touche LLP was ratified.

• Annual meeting resultsJun 13, 2025

  On June 12, 2025, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. The following are the voting results for the proposals considered and voted upon at the meeting... each of the nominees was elected as a Class I director and the appointment of Deloitte & Touche LLP was ratified.

• Charter amendmentFeb 10, 2025

  The Company filed its fifth amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on January 31, 2025... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.

Days to cover

2.3

Short interest

3.8M

Avg volume

1.65M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
  negativeGlobeNewswire Inc.· Oct 6, 2026
• SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
  negativeZacks Investment Research· Sep 16, 2026
• SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Sep 2, 2026
• Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
  negativeGlobeNewswire Inc.· Aug 26, 2026
• Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION)  Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
  negativeGlobeNewswire Inc.· Aug 25, 2026